Logo image
Sign in
Back
Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study
Journal article

Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study

Caitlin L. Soto, Alice J. Hsu, Jae Hyoung Lee, Kathryn Dzintars, Rebecca Choudhury, Timothy C. Jenkins, Erin K. McCreary, Katelyn S. Quartuccio, Erica J. Stohs, Matty Zimmerman, …
Clinical Infectious Diseases, Vol.78(1)
2024
DOI: https://doi.org/10.1093/cid/ciad476

Abstract

Adult Anti-Bacterial Agents Bacteremia Carbapenems Ceftazidime Drug Combinations Hospitals Humans Microbial Sensitivity Tests Sepsis aminoglycoside avibactam plus ceftazidime carbapenem imipenem meropenem meropenem plus vaborbactam polymyxin quinolone derivative antiinfective agent carbapenem derivative ceftazidime aged all cause mortality antibiotic therapy Article bacteremia bloodstream infection carbapenem-resistant Enterobacteriaceae clinical outcome controlled study Enterobacter cloacae female hospital patient human Klebsiella pneumoniae major clinical study male multicenter study nonhuman observational study retrospective study short course therapy adult bacteremia clinical trial drug combination hospital microbial sensitivity test sepsis
In a propensity-score-weighted cohort of 183 adults with carbapenem-resistant Enterobacterales bacteremia at 24 US hospitals, patients receiving short courses of active therapy (7-10 days, median 9 days) experienced similar odds of recurrent bacteremia or death within 30 days as those receiving prolonged courses of active therapy (14-21 days, median 14 days). © 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

Metrics

3 Record Views

Details

Logo image